"All there is to investing is picking good stocks at good times and staying with them as long as they remain good companies", said Warren Buffet, reminding us that patience and discipline are key to successful investing. Stocks quietly climbing to new 52-week highs could be a sign that the market is recognizing consistent performance, strong fundamentals, or upcoming catalysts.The following are some of the stocks that hit new 52-week highs yesterday. Do you already own any of them? Are any on your watchlis ...

Financial Data and Key Metrics Changes - The company reported net revenues of $102.7 million for the last quarter, indicating strong growth since the launch of XDEMVY [2][3] - Guidance for Q3 suggests distribution of 95,000 to 100,000 bottles, reflecting continued market penetration [1][2] - Gross-to-net is expected to decrease to 43% to 45% for Q3, with a target of low 40% by year-end, indicating improved pricing strategies [7][8] Business Line Data and Key Metrics Changes - Over 20,000 eye doctors have prescribed XDEMVY, exceeding initial targets and demonstrating effective market education [3][12] - The company has achieved over 90% insurance coverage for XDEMVY, which is significantly above average in the industry [10][11] Market Data and Key Metrics Changes - The total addressable market (TAM) for Demodex blepharitis is approximately 25 million Americans, with 9 million actively seeking treatment [18][29] - The company anticipates that the TAM could expand as more patients become aware of the treatment options available [18][19] Company Strategy and Development Direction - The company is focused on deepening prescriber engagement and expanding the use cases for XDEMVY among various patient types [4][14] - Plans for international expansion include market entry strategies for Europe and Japan, with a focus on physician education and market development [23][24] Management's Comments on Operating Environment and Future Outlook - Management noted that Q3 typically experiences slower growth due to seasonal factors, but expects robust growth in Q4 as patient visits increase [5][6] - The company is optimistic about maintaining high insurance coverage levels and continuing to grow prescriber engagement [10][11] Other Important Information - The direct-to-consumer (DTC) campaign has been effective in driving awareness and demand, with expectations for continued ROI improvement [16][17] - The company is preparing for the initiation of phase 2 trials for ocular rosacea and Lyme disease prevention, indicating a strong pipeline for future growth [26][31] Q&A Session Summary Question: How should we think about seasonal trends on a go-forward basis? - Management explained that seasonal trends are influenced by market dynamics, with Q4 expected to be stronger due to increased patient flow [5] Question: Could you talk through some of the levers to lower gross-to-net? - Management indicated that gross-to-net discounts typically decrease as patients work through their deductibles, leading to lower discount rates over time [7] Question: What is the expected inventory level moving forward? - The company aims to maintain inventory levels around 2.5 weeks, which is considered optimal for managing demand [9] Question: How do you see the DTC campaign evolving in the next 12 months? - Management expressed confidence in the DTC campaign's effectiveness and expects continued growth in patient engagement and prescriber depth [16] Question: What is the market potential for ocular rosacea? - The market for ocular rosacea is estimated to be 15 to 18 million affected individuals, with significant opportunities for treatment [29]

Financial Data and Key Metrics Changes - The company reported net revenues of $102.7 million for the last quarter, indicating strong growth since the launch of XDEMVY [2][3] - Guidance for Q3 suggests distribution of 95,000 to 100,000 bottles, reflecting a steady cadence of growth despite seasonal dynamics [1][5] - Gross-to-net is expected to decrease to 43% to 45% for Q3, with a target of low 40% by year-end, driven by reduced discounts as patients progress through deductibles [8][9] Business Line Data and Key Metrics Changes - Over 20,000 eye doctors have prescribed XDEMVY, exceeding the initial target of 15,000, showcasing effective market education and engagement [14][15] - The company has achieved over 90% insurance coverage for XDEMVY, which is significantly above the industry average [11][12] Market Data and Key Metrics Changes - The total addressable market (TAM) for Demodex blepharitis is approximately 25 million Americans, with 9 million actively seeking treatment [21][22] - The company anticipates that the TAM could expand as more patients become aware of the treatment options available [21][22] Company Strategy and Development Direction - The company is focused on deepening prescribing patterns among existing prescribers and expanding the use cases for XDEMVY [15][16] - Plans for international expansion include market entry strategies for Europe and Japan, with a focus on physician education and market development [27][29] Management's Comments on Operating Environment and Future Outlook - Management noted that Q4 is expected to be a robust growth quarter as patient visits typically increase post-summer [5][6] - The company is optimistic about maintaining high insurance coverage levels and continuing to grow the prescriber base [11][12] Other Important Information - The company is preparing for the initiation of a phase 2 trial for TP-04 in ocular rosacea, with a focus on specific clinical endpoints [30][31] - The company is also exploring opportunities in Lyme disease prevention with TP-05, which is seen as a complementary program to its eye care focus [35][36] Q&A Session Summary Question: How should we think about seasonal trends on a go-forward basis? - Management explained that seasonal dynamics affect patient flow, with Q4 expected to show robust growth due to increased doctor visits post-summer [5][6] Question: Can you discuss the guidance on gross-to-net? - Management detailed that gross-to-net is expected to decrease as discounts reduce over time, with Q1 typically being the highest discount quarter [8][9] Question: What is the potential for expanding the prescriber base? - Management indicated that while the prescriber base has reached 20,000, the focus will now be on increasing the depth of prescribing among existing prescribers [14][15] Question: What are the expectations for the DTC campaign? - Management expressed confidence in the DTC campaign's effectiveness, anticipating continued growth in awareness and patient engagement [18][19] Question: What is the market potential for ocular rosacea? - Management noted that ocular rosacea affects 15 to 18 million individuals, with significant opportunities for treatment as awareness grows [33][34]

Financial Data and Key Metrics Changes - The company reported net revenues of $102.7 million for the last quarter, indicating strong growth since the launch of XDEMVY [2][3] - Guidance for Q3 suggests distribution of 95,000 to 100,000 bottles, reflecting a steady cadence of growth despite seasonal dynamics [1][5] - Gross-to-net is expected to decrease to 43% to 45% for Q3, with a target of low 40% by year-end, driven by reduced discounts as patients progress through deductibles [8][9] Business Line Data and Key Metrics Changes - Over 20,000 eye doctors have prescribed XDEMVY, exceeding the initial target of 15,000, showcasing effective market education and engagement [14][15] - The company has achieved over 90% insurance coverage for XDEMVY, which is significantly above the industry average [11][12] Market Data and Key Metrics Changes - The total addressable market (TAM) for Demodex blepharitis is approximately 25 million Americans, with 9 million actively seeking treatment, indicating substantial growth potential [21][22] - The company anticipates that the TAM could expand as more patients become aware of the treatment options available [21][22] Company Strategy and Development Direction - The company is focused on deepening prescriber engagement and expanding the utilization of XDEMVY across various patient types, including those with dry eye disease and meibomian gland disease [16][17] - Plans for international expansion include market entry strategies for Europe and Japan, with a focus on physician education and market development [27][29] Management's Comments on Operating Environment and Future Outlook - Management noted that Q3 typically experiences slower growth due to seasonal factors, but expects Q4 to be robust as patient visits increase post-summer [5][6] - The company is optimistic about maintaining high insurance coverage levels and continuing to grow prescriber engagement [11][12] Other Important Information - The company is preparing for the initiation of a phase 2 trial for TP-04 in ocular rosacea, with a focus on specific clinical endpoints [30][31] - The company is also exploring opportunities in Lyme disease prevention with TP-05, which is seen as a complementary program to its eye care focus [35][36] Q&A Session Summary Question: How should we think about seasonal trends on a go-forward basis? - Management explained that seasonal dynamics affect patient flow, with Q3 typically slower due to vacations, but expects robust growth in Q4 [5][6] Question: Can you discuss the guidance on gross-to-net? - Management detailed that gross-to-net discounts are expected to decrease as patients move through their deductibles, with a steady state anticipated in the low 40% range [8][9] Question: What is the potential for expanding the prescriber base? - Management indicated that while the prescriber base has reached 20,000, the focus will now be on increasing the depth of prescribing among existing prescribers [14][15] Question: What are the expectations for the DTC campaign? - Management expressed confidence in the DTC campaign's effectiveness, anticipating continued growth in patient awareness and engagement [18][19] Question: What is the market potential for ocular rosacea? - Management noted that ocular rosacea affects 15 to 18 million individuals, with significant opportunities for treatment as awareness grows [33][34]

Core Insights - The biotech industry is characterized by high risks and potential rewards, where positive news can significantly impact share prices and company viability [1] Group 1: Boston Scientific - Boston Scientific Corp. specializes in medical devices for gastrointestinal and pulmonary conditions, with recent FDA safety alerts affecting its heart devices leading to a temporary dip in share price [2][3] - The company reported a 17% year-over-year (YOY) organic sales increase, with a notable 28% growth for its Watchman device, surpassing analyst expectations for both revenue and earnings [4][5] - Analysts are bullish on Boston Scientific, with 24 out of 26 rating it a Buy and a price target suggesting over 10% upside potential [5] Group 2: Arcutis Biotherapeutics - Arcutis Biotherapeutics focuses on dermatological treatments, with its product ZORYVE driving a remarkable 164% YOY growth in product sales for the latest quarter [6][7] - The FDA approved ZORYVE foam for additional uses, expanding its market reach, and the company anticipates further regulatory decisions later in the year [7][8] - Despite facing competition, Arcutis has a strong pipeline and is rated a Buy by six out of seven analysts, with a potential upside of 24% [8] Group 3: Tarsus Pharmaceuticals - Tarsus Pharmaceuticals specializes in eye care, reporting a net sales beat of nearly $103 million, driven by its Demodex treatment XDEMVY [10][11] - The company is conducting a promising Phase II study for its TP-04 treatment for ocular rosacea, contributing to a positive outlook among analysts [11] - Tarsus shares have increased about 4% year-to-date, with analysts indicating over 16% upside potential [11]

Second Quarter 2025 Financial Results Conference Call August 6, 2025 Matt, an XDEMVY® Patient Today's Speakers Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements and the most recent Form 10-Q quarterly filing filed with the SEC include statemen ...

Core Insights - Tarsus Pharmaceuticals reported record quarterly net product sales of $102.7 million for Q2 2025, marking a 152% increase year over year, driven by the successful launch of XDEMVY [1][5] - The Direct-To-Consumer campaign has significantly increased patient engagement and prescriptions, with active consumer engagement on the XDEMVY website up nearly 400% since the start of 2025 [5] - The company is on track with its pipeline advancements and global expansion efforts, including plans for regulatory meetings in Japan and potential European approval for a preservative-free formulation of XDEMVY [5][10] Recent Business and Clinical Highlights - XDEMVY has established itself as the standard of care for Demodex blepharitis, with over 91,000 bottles distributed in Q2 2025 [2][5] - More than 20,000 Eye Care Professionals (ECPs) are now prescribing XDEMVY, a 30% increase since the beginning of 2025 [5] - The company plans to initiate a Phase 2 study of TP-04 for ocular rosacea in H2 2025 and a Phase 2 study of TP-05 for Lyme disease prevention in 2026 [5] Financial Results - For Q2 2025, product sales were $102.7 million compared to $40.8 million in Q2 2024, with a total of approximately 91,000 bottles delivered [5][10] - Cost of sales increased to $6.2 million from $3.0 million in the same period last year, primarily due to manufacturing costs related to XDEMVY [10] - Research and development expenses rose to $15.6 million from $12.3 million in Q2 2024, driven by increased program expenses and personnel-related costs [6][10] Year-to-Date Financial Performance - Year-to-date product sales reached $181.0 million, up from $65.5 million in the same period in 2024 [10] - Selling, general and administrative expenses increased to $188.0 million from $110.4 million, largely due to higher commercial and marketing costs associated with the XDEMVY launch [10] - The net loss for the year-to-date period was $45.5 million, an improvement from a net loss of $69.0 million in the same period in 2024 [10]

Core Insights - Tarsus Pharmaceuticals reported a significant increase in net product sales of XDEMVY, reaching $78.3 million, which represents a 217% year-over-year growth and an 18% increase over Q4 2024 [4][10] - The company has strengthened its financial position by raising approximately $135 million through a public equity offering, resulting in cash, cash equivalents, and marketable securities totaling approximately $408 million as of March 31, 2025 [4][10] - Tarsus is on track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the treatment of Ocular Rosacea in the second half of 2025 [4][10] Financial Performance - The first quarter of 2025 saw net product sales of XDEMVY at $78.3 million compared to $24.7 million in the same period of 2024, driven by approximately 72,000 bottles delivered to patients, up from 26,000 bottles year-over-year [10][19] - Cost of sales increased to $5.2 million from $1.7 million in the prior year, attributed to manufacturing costs and royalties [10][19] - Research and development expenses rose to $14.4 million from $12.1 million, while selling, general, and administrative expenses increased to $85.0 million from $51.6 million, primarily due to higher payroll and marketing costs [10][19] - The net loss for the quarter was $25.1 million, an improvement from a net loss of $35.7 million in the same quarter of 2024, with a basic and diluted net loss per share of $(0.64) compared to $(1.01) [10][19] Business Highlights - XDEMVY is positioned to be one of the fastest-growing anterior segment medicines, with broad commercial reimbursement coverage extending to over 90% of covered lives [4][10] - The company reported a gross-to-net discount of approximately 47% and a 23% increase in the number of bottles dispensed compared to Q4 2024 [4][10] - Direct-to-consumer advertising led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [4][10] - Tarsus is advancing its pipeline with multiple catalysts expected in 2025, including a meeting with regulatory authorities in Japan to discuss the regulatory path for XDEMVY [4][10] Pipeline Developments - Tarsus is on track to initiate a Phase 2 study of TP-04 for Ocular Rosacea, a condition with no FDA-approved therapy, in H2 2025 [4][10] - The company is also developing TP-05, an investigational oral tablet for the potential prevention of Lyme disease, expected to begin trials in 2026 [5][10]